CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics is attractive because CTX310 is showing durable, one-time gene-editing effects with one-year ANGPTL3 reduction of 78.6% at the highest dose, alongside meaningful LDL-cholesterol and triglyceride declines, which supports proof-of-concept in cardiovascular disease. The safety profile also looks manageable so far, with no new treatment-related serious adverse events and only transient liver enzyme elevation at the top dose, while the company’s broader pipeline and Casgevy provide additional upside beyond the lipid program. Fundamentally, the outlook is strengthened by a relatively well-funded platform, with about $2.1 billion in estimated YE:26 cash, and by the possibility that CTX310 can compete in severe hypertriglyceridemia through differentiated, one-and-done efficacy.

CRISPR Therapeutics is challenged by a highly uncertain CRISPR/Cas9 intellectual property position, dependence on third-party patent rights, and the possibility that pending protections may not materialize or could be infringed, all of which weaken the durability of its platform economics. Its pipeline also faces substantial clinical and competitive risk, with possible failures across exa-cel, CTX112, CTX310, CTX340, CTX460, and CTX611, while a setback could damage confidence in the broader technology and pressure adoption of Casgevy if sales fail to accelerate. Financially, the company may need a secondary offering to fund development, creating dilution risk, and any disruption to partnerships with Vertex, Bayer, or others could further hurt shareholder value.